EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
BMC CANCER. Bd. 19. 2019
Erscheinungsjahr: 2019
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Wagner, Anna Dorothea (Autor)
Grabsch, ? (Autor)
Mauer, Murielle (Autor)
Marreaud, Sandrine (Autor)
Caballero, Carmela (Autor)
Thuss-Patience, Peter (Autor)
Mueller, Lothar (Autor)
Elme, Annelie (Autor)
Moehler, Markus Hermann (Autor)
Martens, Uwe (Autor)
Kang, Yoon-Koo (Autor)
Rha, Sun Young (Autor)
Cats, Annemieke (Autor)
Tokunaga, Masanori (Autor)
Lordick, Florian (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
